Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

RAL-eve Study: Raltegravir Substitution Study

This study has been completed.
Information provided by (Responsible Party):
Stanford University Identifier:
First received: August 29, 2007
Last updated: October 31, 2011
Last verified: October 2011

The purpose of this study is to:

  • Provide raltegravir to subjects with HIV and an undetectable viral load who are experiencing injection site reactions (ISR) to Enfuvirtide,
  • Monitor the safety and efficacy of raltegravir, and
  • Assess the change in quality of life in patients who have switched from Enfuvirtide to raltegravir

Condition Intervention
HIV Infections
Drug: Raltegravir

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Raltegravir Substitution for Enfuvirtide in Patients Suffering From Injection Site Reactions (ISRs): The Raleve Pilot Study

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • The Percentage of Patients Who Maintain a Viral Load < 50 Copies/ml After Being Switched From Enfuvirtide to Raltegravir [ Time Frame: 24 weeks ]
    evaluate the percent of patients with viral load of <50 copies at week 24 of study after being switched from enfuvirtide to raltegravir

Enrollment: 14
Study Start Date: October 2007
Study Completion Date: December 2010
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Raltegravir
    400 mg Twice daily for 24 weeks
    Other Name: Isentress
Detailed Description:
We enrolled virologically suppressed HIV-1 infected patients with injection site reactions for a switch from enfuvirtide to raltegravir. At baseline, enfuvirtide was switched to raltegravir without additional changes to the antiretroviral regimen allowed. Viral load, T-cells, and toxicity were evaluated at baseline, 2, 4, 12 and 24 weeks. Adherence and injection site reactions were evaluated at baseline, 4, 12 and 24 weeks. The single-copy assay was used to measure HIV RNA levels at screening, baseline and at 12 and 24 weeks.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry.
  2. ART for at least 6 months prior to study entry with a regimen that includes enfuvirtide.
  3. Self-defined infusion site reaction to enfuvirtide (usually will be painful inflammatory nodules)
  4. No change in ART regimen for at least 3 months prior to study entry.
  5. CD4+ cell count >50/mm3 at screening (obtained within 60 days prior to study entry).
  6. Documentation of HIV-1 RNA below the limit of quantification of an ultrasensitive assay
  7. All HIV-1 RNA levels obtained within 6 months prior to study entry are below the limits of quantification on all tests, except as explained above in section 4.1.6 for a single detectable viral load of <50 copies but <200 copies in last 6 months.
  8. Laboratory values obtained within 60 days prior to entry:

    • Absolute neutrophil count (ANC) >750/mm3
    • Hemoglobin >9.0 g/dL for female subjects and>10.0 g/dL for male subjects
    • Platelet count >50,000/mm3
    • Calculated creatinine clearance (CrCl) >30 mL/min, as estimated by the Cockcroft-Gault equation*
    • AST (SGOT), ALT (SGPT), and alkaline phosphatase <5 x ULN
    • Total bilirubin <2.5 x ULN. If the subject is taking an indinavir- or atazanavir-containing regimen at the time of screening, total bilirubin <5 x ULN is acceptable.
  9. For females of reproductive potential will need a negative serum or urine pregnancy test within 48 hours prior to entry.
  10. Men and women age >18 years.
  11. Ability and willingness of subject to provide informed consent.

Exclusion Criteria:

  1. Unstable clinical condition, such as unstable cardiac disease, or cancer requiring ongoing chemotherapy or radiation therapy, or other medical condition which, in the opinion of the investigator, would preclude a subject from safely undergoing study procedures.
  2. Breast-feeding or pregnancy.
  3. An opportunistic infection within 60 days prior to entry.
  4. Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or their formulation.
  5. Active drug or alcohol use or dependence that, in the opinion of the Protocol Director, would interfere with adherence to study requirements.
  6. Receipt of a non-HIV vaccination within 30 days prior to study entry or plan for receipt of vaccination during the study.
  7. Plan to change the background ART within 24 weeks after study entry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00523237

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Principal Investigator: Andrew R Zolopa Stanford University
  More Information

Responsible Party: Stanford University Identifier: NCT00523237     History of Changes
Obsolete Identifiers: NCT00627939
Other Study ID Numbers: RAL-eve study
Study First Received: August 29, 2007
Results First Received: July 20, 2011
Last Updated: October 31, 2011

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Raltegravir Potassium
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
HIV Integrase Inhibitors
Integrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017